Answers are grounded in this paper and cite their sources.
K+ channel openers represent a novel pharmacological principle in cardiovascular medicine with vasodilatory and potential cardioprotective effects.
Many drugs used in cardiology act by chang- ing the gating properties of ion channels. This is true for Cal+ antagonists which are blockers of voltage-operated L-type Ca2+ channels and for most antiarrhythmics. Class I agents are blockers of Na+ channels whereas class III antiarrhythmics prolong the cardiac action potential by blockade of K+ channels.' In the past decade much has been learnt about the physiology and pharmacology of ion channels. Pharmacological agents that selectively open K+ channels have been developed and this novel group of drugs is rapidly expanding.23 K+ channel openers are peripheral and coronary vasodilators45 but they additionally act on the myocardium and seem to protect it from damage during ischaemia and reperfusion.67
No takes yet. Share an insight, caveat, or question.
Nielsen‐Kudsk et al. (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: